Fonte: Oncotarget. Unidade: ICB
Assuntos: GLIOMA, MELANOMA, NEOPLASIAS, FÁRMACOS, TERAPÊUTICA, DNA, ESTRESSE OXIDATIVO, MICROBIOLOGIA
ABNT
ROCHA, Clarissa Ribeiro Reily et al. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget, v. 7, n. 30, p. 48081-48092, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.10129. Acesso em: 05 set. 2024.APA
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016). NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget, 7( 30), 48081-48092. doi:10.18632/oncotarget.10129NLM
Rocha CRR, Kajitani GS, Quinet A, Fortunato RS, Menck CFM. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells [Internet]. Oncotarget. 2016 ; 7( 30): 48081-48092.[citado 2024 set. 05 ] Available from: https://doi.org/10.18632/oncotarget.10129Vancouver
Rocha CRR, Kajitani GS, Quinet A, Fortunato RS, Menck CFM. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells [Internet]. Oncotarget. 2016 ; 7( 30): 48081-48092.[citado 2024 set. 05 ] Available from: https://doi.org/10.18632/oncotarget.10129